Showing 261 - 280 results of 761 for search '"placebo"', query time: 0.04s Refine Results
  1. 261

    Efficacy of clomiphene citrate and tamoxifen on pregnancy rates in idiopathic male subfertility: A systematic review and meta-analysis by Shadi Khashaba, Shehab Khashaba, Anil Krishan, Angus Bruce, Abdullatif Almaghlouth, Jason Huang, Mahmoud Mima, Craig Niederberger

    Published 2025-01-01
    “…Clomiphene citrate and placebo groups had similar pregnancy rates (10.4% and 7.1%, respectively; odds ratio 1.30 [95% confidence interval 0.27–6.17]; p=0.74). …”
    Get full text
    Article
  2. 262
  3. 263

    The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain by Feryal Al-Saber, Waleed Aldosari, Mariam Alselaiti, Hesham Khalfan, Ahmed Kaladari, Ghulam Khan, George Harb, Riyadh Rehani, Sizuka Kudo, Aya Koda, Tohru Tanaka, Motowo Nakajima, Abdulla Darwish

    Published 2016-01-01
    “…Waleed (Site #03) (n=35, 5-ALA-SFC; n=18, placebo). There was no significant difference in incidence of adverse events reported, and the most frequent events reported were gastrointestinal in nature, consistent with the known safety profile of 5-ALA in patients with diabetes. …”
    Get full text
    Article
  4. 264

    Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials by Lina Tao, Xiaoyu Qu, Yue Zhang, Yanqing Song, Si-xi Zhang

    Published 2019-01-01
    “…Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. …”
    Get full text
    Article
  5. 265

    Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS... by Gareth Jones, Mark I. Johnson, Carole A. Paley, Matthew R. Mulvey, Priscilla G. Wittkopf

    Published 2022-02-01
    “…Pain intensity was lower during or immediately after TENS compared with placebo (91 RCTs, 92 samples, n=4841, SMD=−0·96 (95% CI −1·14 to –0·78), moderate-certainty evidence). …”
    Get full text
    Article
  6. 266

    Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission by C. A. M. Wegh, N. M. de Roos, R. Hovenier, J. Meijerink, I. Besseling-van der Vaart, S. van Hemert, B. J. M. Witteman

    Published 2019-01-01
    “…Methods. In this twelve-week placebo-controlled randomized double-blind study, twenty-five subjects with UC in remission received either placebo or a multispecies probiotics. …”
    Get full text
    Article
  7. 267

    The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib by Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Hendrik Schulze-Koops, Haruhiko Fukada, Chris Watson, Tsutomu Takeuchi

    Published 2024-11-01
    “…Only FIL200 significantly inhibited joint damage compared with placebo in patients with MDA or HDA, indicating an uncoupling of clinical disease activity and structural progression in patients receiving FIL200. …”
    Get full text
    Article
  8. 268

    Patient Perspectives on Evolving Diverticulitis Treatment: An Assessment of Patient Willingness to Enroll in a Randomized Controlled Trial by Annie Altman-Merino, MD, Kemberlee Bonnet, MA, David Schlundt, PhD, Jesse Wrenn, MD, PhD, Wesley H. Self, MD, MPH, Elisa J. Gordon, PhD, MPH, Alexander T. Hawkins, MD, MPH

    Published 2024-09-01
    “…The objective of the study was to assess patients’ attitudes regarding participation in a randomized trial of antibiotics versus placebo for acute diverticulitis. Background:. Despite evidence that antibiotics may not be necessary to treat acute uncomplicated diverticulitis, they remain the mainstay of treatment in the United States. …”
    Get full text
    Article
  9. 269

    Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis by Frank Buttgereit, Rieke Alten, Amy Grahn, Robert J Holt, Patricia Rice

    Published 2015-08-01
    “…General quality of life was assessed using the general score and individual domains of Functional Assessment of Cancer Therapy-General (FACT-G) and SF-36.Results The change from baseline to week 12 in FACIT-F score was statistically significantly different with DR prednisone/DMARD (3.8) versus placebo/DMARD (1.6; difference 2.2, p=0.0032). Improvement in FACIT-F score correlated positively with clinical response. …”
    Get full text
    Article
  10. 270

    Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies by Ying Liu, Lin Wu, Dingzhi Huang, Qiming Wang, Chen Yang, Li Zhou, Shuguang Sun, Xiaomei Jiang, Ying Cheng

    Published 2024-01-01
    “…Overall, the median progression-free survival was 5.3 months in the trilaciclib and 4.9 months in the placebo group. The median overall survival was 10.9 months in the trilaciclib and 10.1 months in the placebo group. …”
    Get full text
    Article
  11. 271

    Effects of olive leaf extract on exercise performance and muscle mitochondrial response in young healthy adults by Clément Lanfranchi, Nadège Zanou, Jérôme Feige, Umberto DeMarchi, Aurélie Hermant, Ornella Cominetti, Eugenia Migliavacca, Alba Moreno-Asso, Astrid Hostrman, Sara Mistro, Nicolas Place

    Published 2025-01-01
    “…Methods In a crossover (OLE vs. placebo), double-blind study, eleven healthy males performed a single session of MICT (1h at 50% maximal aerobic power). …”
    Get full text
    Article
  12. 272
  13. 273

    Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial. by Dimuthu Muthukuda, Chamini Kanatiwela de Silva, Saumiyah Ajanthan, Namal Wijesinghe, Anuradha Dahanayaka, Arunasalam Pathmeswaran

    Published 2025-01-01
    “…<h4>Materials and methods</h4>This was a randomized, double-blinded, placebo-controlled clinical trial. Participants were allocated to either C. zeylanicum extract or placebo group (1:1 allocation ratio). …”
    Get full text
    Article
  14. 274

    Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials by Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho

    Published 2025-01-01
    “…Dupilumab probably has no meaningful effect on FEV1 compared to placebo (MD 0.07 [95% CI 0.02 to 0.13]) (moderate certainty). …”
    Get full text
    Article
  15. 275

    Application of glycyrrhizinic acid in treatment of patients with alcoholic liver disease by I. G. Nikitin, I. Ye. Baykova, V. M. Volynkina, L. M. Gogova, G. I. Storozhakov, M. P. Prushkovskaya

    Published 2009-02-01
    “…The level of tumor necrosis factor-α significantly differed and was equal to 796,8±89,9 mcmol/l in patients receiving placebo, and 412,8±76,8 mcmol/l in group, receiving glycyrrhizinic acid (p&gt;&lt;0,01). …”
    Get full text
    Article
  16. 276

    Comparative assessment of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> and <i>Saccharomyces boulardii</i> efficacy at d... by V. T. Ivashkin, O. M. Drapkina, A. A. Sheptulin, O. S. Shifrin, Ye. A. Poluektova, S. Yu. Kuchumova

    Published 2015-05-01
    “…In group of the patients who received Florasan-D and Enterol, in contrast to as placebo group improvement in relation to severity of main clinical symptoms was marked, quality of a life score increased. …”
    Get full text
    Article
  17. 277

    Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review an... by Lei Tian, Mengdi Wang, Mengchao Liu, Yanyu Pang, Jingwen Zhao, Bingjie Zheng, Yutong Wang, Wenjing Zhao

    Published 2024-12-01
    “…No significant difference was observed in the risk of kidney-related adverse events when comparing roxadustat with the placebo (RR = 1.088; CI [0.980 to 1.209]) or ESA (RR = 0.968; CI [0.831 to 1.152]), in DD (RR = 2.649; CI [0.201 to 34.981]) or NDD (RR = 1.053; CI [0.965 to 1.149]) CKD patients. …”
    Get full text
    Article
  18. 278

    Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review. by Dan-Jie Zhao, Xia Li, Hai-Xia Lin, Hong Zheng, Di Zhou, Peng Tang

    Published 2024-01-01
    “…The results revealed that the 15 mg and 30 mg upadacitinib significantly improved Eczema Area and Severity Index (EASI) 75% {[Odds Ratio (OR) = 8.58, 95% confidence interval (CI) (5.84-12.60), P < 0.00001] [OR = 15.62, 95% CI (10.89-22.42), P < 0.00001]}, Numerical Rating Scale (NRS) ≥ 4 {[OR = 7.13, 95% CI (5.63-9.01), P < 0.00001] [OR = 11.30, 95% CI (8.93-14.31), P < 0.00001]}, and Investigator's Global Assessment (IGA) 0/1 {[OR = 8.63, 95% CI (6.60-11.27), P < 0.00001] [OR = 16.04, 95% CI (12.26-20.99), P < 0.00001]} compared to placebo. In terms of safety, although 15 mg and 30 mg upadacitinib significantly increased the overall adverse events rate compared to placebo {[OR = 1.31, 95% CI (1.09-1.58), P = 0.004] [OR = 1.85, 95% CI (1.54-2.21), P < 0.00001]}, there was no significant difference in the serious adverse events rate {[OR = 0.73, 95% CI (0.41-1.29), P = 0.28] [OR = 0.69, 95% CI (0.39-1.23), P = 0.21]} and withdrawal rate due to adverse events {[OR = 0.66, 95% CI (0.39-1.11), P = 0.12] [OR = 0.85, 95% CI (0.52-1.38), P = 0.50]} compared to placebo.…”
    Get full text
    Article
  19. 279
  20. 280